EGFR and neoplasm: Ultimately, increased EREG and AREG from any source may confer resistance by outcompeting EGFR-targeted mAbs for EGFR binding, thus re-activating EGFR and promoting tumor growth even in the presence of EGFR-targeted mAbs.